Avecho Biotechnology Limited (AU:AVE)
ASX:AVE
Want to see AU:AVE full AI Analyst Report?
AVE Stock Chart & Stats
AU$0.01
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.01
AU$0.00(0.00%)
Day’s Range― - ―
52-Week Range<AU$0.01 - AU$0.01
Previous CloseN/A
Volume188.16K
Average Volume (3M)N/A
Market Cap
AU$47.85M
Enterprise ValueAU$33.92M
Total Cash (Recent Filing)AU$4.66M
Total Debt (Recent Filing)AU$14.47K
Price to Earnings (P/E)―
Beta0.94
Next Earnings
Aug 31, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding3,680,464,400
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio-0.17
Price to Book (P/B)18.85
Price to Sales (P/S)23.75
P/FCF Ratio26.65
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary TPM PlatformAvecho’s TPM is a durable technical asset that supports formulation and absorption advantages across pharmaceuticals and nutraceuticals. As a platform it enables licensing, partner co-development, and recurring royalties, creating scalable, asset-light growth pathways over months to years.
Improved Cash GenerationThe 2025 swing to positive operating and free cash flow demonstrates the company can generate internal funding after prolonged burn. This strengthens near-term self-funding for R&D or partner deals, reduces immediate financing pressure and improves negotiating leverage with collaborators.
Low Leverage / Manageable DebtVery low debt gives Avecho financial flexibility to invest in development or absorb timing delays without heavy interest burdens. Manageable leverage preserves cash available for commercialisation, licensing activities and milestone funding, supporting execution over the next several quarters.
Bears Say
Persistent Operating And Net LossesSustained, sizable operating and net losses indicate the business has not yet achieved profitable scale. Continued deficits can force dilutive capital raises, constrain R&D prioritisation, and erode investor confidence, posing a structural risk to capital continuity if profitability isn’t reached.
Shrinking Equity BaseA falling equity base reduces the balance-sheet buffer against future losses and makes the company more sensitive to shocks. Shrinking net assets limit strategic optionality, increase the relative impact of any new debt or dilution, and heighten the risk profile for partners and lenders.
Volatile Cash Flows HistoricallyThe abrupt cash-flow swing signals unpredictability in operating cash generation. Such volatility complicates planning for regulatory milestones, partner commitments and product launches; it raises the chance that cash generation could revert, requiring fresh financing or curtailed programs.
Avecho Biotechnology Limited News
AVE FAQ
What was Avecho Biotechnology Limited’s price range in the past 12 months?
Avecho Biotechnology Limited lowest share price was <AU$0.01 and its highest was AU$0.01 in the past 12 months.
What is Avecho Biotechnology Limited’s market cap?
Avecho Biotechnology Limited’s market cap is AU$47.85M.
When is Avecho Biotechnology Limited’s upcoming earnings report date?
Avecho Biotechnology Limited’s upcoming earnings report date is Aug 31, 2026 which is in 113 days.
How were Avecho Biotechnology Limited’s earnings last quarter?
Avecho Biotechnology Limited released its earnings results on Feb 27, 2026. The company reported AU$0 earnings per share for the quarter, the consensus estimate of N/A by AU$0.
Is Avecho Biotechnology Limited overvalued?
According to Wall Street analysts Avecho Biotechnology Limited’s price is currently Overvalued.
Does Avecho Biotechnology Limited pay dividends?
Avecho Biotechnology Limited does not currently pay dividends.
What is Avecho Biotechnology Limited’s EPS estimate?
Avecho Biotechnology Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Avecho Biotechnology Limited have?
Avecho Biotechnology Limited has 3,680,464,400 shares outstanding.
What happened to Avecho Biotechnology Limited’s price movement after its last earnings report?
Avecho Biotechnology Limited reported an EPS of AU$0 in its last earnings report, expectations of N/A. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Avecho Biotechnology Limited?
Currently, no hedge funds are holding shares in AU:AVE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Avecho Biotechnology Limited Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Fundamentals
Return on Equity
-370.40%
Trailing 12-Months
Asset Growth
42.21%
Trailing 12-Months
Company Description
Avecho Biotechnology Limited
Avecho Biotechnology Limited, a biotechnology company, develops, produces, and sells products using its patented platform technology, Targeted Penetration Matrix (TPM) drug delivery system for the pharmaceutical, skin care, animal health, and nutrition industries. It offers TPM and Vital ET products for use in drug delivery and cosmetic formulations; and develops TPM/Oxymorphone and TPM/Oxycodone. The company's human health portfolio covers delivery of pharmaceutical products through gels, injectables, and patches. It also provides non-antibiotic feed additive products to enhance feed efficiency and the health of livestock animals. The company has a collaboration with Lambert Initiative at the University of Sydney to conduct a study to examine whether topically applied cannabidiol can provide relief from symptoms of osteoarthritis. It serves customers in Australia, Switzerland, India, and internationally. The company was formerly known as Phosphagenics Limited and changed its name to Avecho Biotechnology Limited in May 2019. Avecho Biotechnology Limited was incorporated in 1992 and is based in Clayton, Australia.
Technical Analysis
Living Cell Technologies
―
Immuron Limited
―
Noxopharm Ltd.
―
Chimeric Therapeutics Ltd.
―
Memphasys Ltd
―